PET developer Naviscan is highlighting clinical trial results that show positron emission mammography (PEM) imaging with a breast-cancer-specific tracer achieved 100% sensitivity.
Mathew Thakur, PhD, of Thomas Jefferson University, and colleagues performed PEM imaging using both the cancer-specific radiotracer copper-64 (Cu-64) TP3805 and F-18 FDG in 13 patients. Results were published in the July issue of the Journal of Nuclear Medicine (Vol. 54:7, pp. 1019-1025).
PEM with TP3805 identified all of the 20 malignant lesions in the patient cohort, according to Naviscan. The images were acquired with Naviscan's PET scanner
TP3805 is licensed by NuView Life Sciences. It binds to receptors found on all breast cancer cells early in malignant transformation, Naviscan said.
